The Executive Committee of the American Joint Committee on Cancer (AJCC) named Mahul B. Amin, MD, FCAP, Editor-in-Chief of the upcoming eighth edition of the AJCC Cancer Staging Manual. Dr. Amin is chairman and professor of the department of pathology and laboratory medicine at Cedars-Sinai Medical Center, Los Angeles, CA. Programs of the AJCC, established in 1959, are administered by the American College of Surgeons (ACS).
The AJCC Cancer Staging Manual provides physicians and health care professionals around the world with a tool to facilitate the uniform description and reporting of cancer. The manual presents evidence-based criteria for the staging of cancer for a number of anatomic disease sites, which includes the rationale and rules for staging; the definitions of tumor, lymph node involvement, and metastasis; stage groupings; and histologic grade.
Dr. Amin is a nationally and internationally recognized expert in tumors of the genitourinary tract including prostate, urinary bladder, kidney, and testis. He earned his medical degree from G.S. Medical College and King Edward Memorial Hospital in Bombay, India. He served on the executive committee of the AJCC from 2003 to 2011.
“He brings a multidisciplinary approach to the editor-in-chief position, in addition to a molecular-based medical perspective of cancer staging. These approaches are important since, for this latest edition, we’re stabilizing anatomic staging and expanding the focus on personalized medicine using molecular markers,” David P. Winchester, MD, FACS, Medical Director of the ACS Cancer Programs, said.
he eighth edition of the Cancer Staging Manual—which is expected to be published in late 2015 for patients diagnosed with cancer after January 2016—will incorporate advances made in cancer research, staging, diagnosis, and treatment since the seventh edition was published in October 2009. More than 500 cancer experts from around the world will collaborate on the manual, covering more than 60 primary disease sites.
“There have been enormous advances in cancer diagnosis, staging, and treatment since the results of the Human Cancer Genome Project were first announced more than a decade ago,” Dr. Amin said. “As a result, we can better predict the level of cancer risk and tailor a more personalized treatment program for the patient. For the eighth edition, we will incorporate these newer precision medicine paradigms, as appropriate, into the more traditional anatomic extent of disease premise of the AJCC staging classification.”